Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Antivenin Centruroides Scorpion Equine Immune Fab2

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total
Phase 2/3 (2)
Phase 3 (1)

Trial Status

Completed4

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 4 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT01599923Phase 3CompletedPrimary

Open Label Study of Alacramyn® in Pediatric Patients With Scorpion Sting Envenomation

NCT00685230Phase 2/3CompletedPrimary

Double-Blind, Alacramyn® vs. Placebo in Pediatric Patients

NCT00624078Phase 2/3CompletedPrimary

Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting Envenomation

NCT00696683CompletedPrimary

Establishment of Natural History of Scorpion Envenomation

Showing all 4 trials

Research Network

Common Treatments

  • Antivenin Centruroides Scorpion Equine Immune Fab22
  • None This Is An Observational Study1
  • Antivenin Centruroides Scorpion Fab2 Anascorp1

Active Sponsors

  • University of Arizona4
  • Instituto Bioclon S.A. de C.V.4
  • Universidad Nacional Autonoma de Mexico2

Top Investigators

Activity Timeline